Literature DB >> 24976709

Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.

Kuang-Chun Hu1, Horng-Yuan Wang1, Sung-Chen Liu1, Chuan-Chuan Liu1, Chung-Lieh Hung1, Ming-Jong Bair1, Chun-Jen Liu1, Ming-Shiang Wu1, Shou-Chuan Shih1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) refers to the accumulation of fat (mainly triglycerides) within hepatocytes. Approximately 20%-30% of adults in the general population in developed countries have NAFLD; this trend is increasing because of the pandemicity of obesity and diabetes, and is becoming a serious public health burden. Twenty percent of individuals with NAFLD develop chronic hepatic inflammation [nonalcoholic steatohepatitis (NASH)], which can be associated with the development of cirrhosis, portal hypertension, and hepatocellular carcinoma in a minority of patients. And thus, the detection and diagnosis of NAFLD is important for general practitioners. Liver biopsy is the gold standard for diagnosing NAFLD and confirming the presence of NASH. However, the invasiveness of this procedure limits its application to screening the general population or patients with contraindications for liver biopsy. The development of noninvasive diagnostic methods for NAFLD is of paramount importance. This review focuses on the updates of noninvasive diagnosis of NAFLD. Besides, we review clinical evidence supporting a strong association between NAFLD and the risk of cardiovascular disease because of the cross link between these two disorders.

Entities:  

Keywords:  Cardiovascular disease; Image assessment; Laboratory biochemistry; Nonalcoholic fatty liver disease; Noninvasive diagnosis

Mesh:

Substances:

Year:  2014        PMID: 24976709      PMCID: PMC4069300          DOI: 10.3748/wjg.v20.i24.7718

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  90 in total

1.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 2.  Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.

Authors:  Leon A Adams; Ariel E Feldstein
Journal:  J Dig Dis       Date:  2011-02       Impact factor: 2.325

3.  Are we overestimating the risks of NASH?

Authors:  Varghese Thomas; Kareem Harish
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

Review 4.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

Review 5.  Apoptosis in alcoholic and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Front Biosci       Date:  2005-09-01

6.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

7.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

8.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

10.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04
View more
  9 in total

Review 1.  Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Ayman Abouleid; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

2.  Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model.

Authors:  Hyunsoo Chung; Young Eun Chon; Seung Up Kim; Sang Kil Lee; Kyu Sik Jung; Kwang-Hyub Han; Chae Yoon Chon
Journal:  Dig Dis Sci       Date:  2015-10-06       Impact factor: 3.199

3.  Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease.

Authors:  Chia-Chu Chang; Chia-Lin Wu; Wei-Wen Su; Kai-Lun Shih; Der-Cherng Tarng; Chen-Te Chou; Ting-Yu Chen; Chew-Teng Kor; Hung-Ming Wu
Journal:  Sci Rep       Date:  2015-05-11       Impact factor: 4.379

4.  Prevention Mechanism of 2,3,5,4'-Tetrahydroxy-stilbene-2-O-β-D-glucoside on Lipid Accumulation in Steatosis Hepatic L-02 Cell.

Authors:  Pei Lin; Jian-Mei Lu; Yan-Fang Wang; Wen Gu; Rong-Hua Zhao; Jie Yu
Journal:  Pharmacogn Mag       Date:  2017-04-18       Impact factor: 1.085

5.  The effect of total anthocyanin-base standardized (Cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: a study protocol for a double-blind randomized clinical trial.

Authors:  Zohreh Sadat Sangsefidi; Mahdieh Hosseinzadeh; Ali Mohammad Ranjbar; Mohsen Akhondi-Meybodi; Hossein Fallahzadeh; Hassan Mozaffari-Khosravi
Journal:  Nutr J       Date:  2019-07-19       Impact factor: 3.271

6.  Nonalcoholic fatty liver disease in lean and obese patients in Saudi patients from a single center.

Authors:  Khalid A Alsuhaibani; Faris S Althunayyan; Ali M Alsudays; Ahmad A Alharbi; Badr M Aljarallah
Journal:  J Family Med Prim Care       Date:  2021-09-30

7.  Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review.

Authors:  Huanqiu Wang; Ruyu Sun; Sisi Yang; Xueqing Ma; Chengbo Yu
Journal:  Front Med (Lausanne)       Date:  2022-08-03

8.  The Use of Computed Tomography in the Diagnosis of Fatty Liver and Abdominal Fat Distribution among a Saudi Population.

Authors:  Gasim Ibrahim Gasim; Fahd Mohamed Elshehri; Mahmoud Kheidr; Fahad Khalid Alshubaily; ElZaki Mohamed ElZaki; Imad R Musa
Journal:  Open Access Maced J Med Sci       Date:  2017-10-14

9.  Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases.

Authors:  A Mojtahed; C J Kelly; A H Herlihy; S Kin; H R Wilman; A McKay; M Kelly; M Milanesi; S Neubauer; E L Thomas; J D Bell; R Banerjee; M Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2019-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.